CTLA4 and colon carcinoma: In our previous studies, we have found that intratumoral NDV could potentiate the efficacy of systemic CTLA-4 blockade in the B16 model, which reasonably supports NDV infection, as well as TRAMP C2 prostate adenocarcinoma and CT26 colon carcinoma, which have poor permissiveness for NDV13.